Axel Heidenreich

Sep 15, 2024 | urotoday.com | Axel Heidenreich

Read the Full Video TranscriptZach Klaassen: Hi, my name is Zach Klaassen. I'm a urologic oncologist at the Georgia Cancer Center in Augusta, Georgia. I'm delighted to be joined on UroToday by Dr. Axel Heidenreich, who's a urologic oncologist at the University of Cologne in Germany. Axel, thanks very much for joining us today on UroToday. Axel Heidenreich: No, thank you very much for the invitation.

Apr 9, 2024 | urologic.theclinics.com | Axel Heidenreich |David G. Pfister

Keywords Germ cell tumor Retroperitoneal lymphadenectomy Retroperitoneal lymph node dissection Seminoma Nonseminoma PEB To read this article in full you will need to make a payment Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access One-time access price info For academic or personal research use, select 'Academic and Personal' For corporate R&D use, select 'Corporate R&D Professionals' Subscribers receive full online access to your subscription and...

Sep 30, 2023 | nature.com | Jakob Lauritsen |Di Jiang |Robert Huddart |Michal Chovanec |Christian D Fankhauser |Axel Heidenreich | +1 more

AbstractActive surveillance after orchiectomy is the preferred management in clinical stage I (CSI) germ-cell tumours (GCT) associated with a 15 to 30% relapse rate. In the IGCCCG Update database, we compared the outcomes of gonadal disseminated GCT relapsing from initial CSI to outcomes of patients with de novo metastatic GCT.